Federal Circuit Won’t Rehear Induced Infringement Arguments For Generic Drug
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals denied a biopharmaceutical company’s petition for rehearing en banc in a July 1 order, rejecting the company’s contention that an appeals...To view the full article, register now.
Already a subscriber? Click here to view full article